Month: 2025-05

Key Highlights- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune disease- Milder T cell activation than Blincyto and Target cell-dependent T cell activation- Multiple CR cases observed in ongoing r/r NHL Phase Ia trial and r/r ALL Phase Ib/II trialHONG KONG, May 29, 2025 - (ACN Newswire via SeaPRwire.com) – Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager that entered into clinical trial for primary membranous nephropathy (pMN). The patient remained well after administration with no adverse reactions witnessed to date.pMN is an autoimmune disease caused by the attack of autoantibodies against podocyte antigens leading to the in situ production of immune complexes. pMN is the most common cause of primary nephrotic syndrome in non-diabetic adults worldwide, accounting for 20% to 37% of affected individuals, and as high as 40% in adults over 60 years of age (1). Currently, 20-30% of pMN cases are resistant to current therapies like rituximab and cyclophosphamide and relapse rates can be high (2).A clear regulatory pathway in this orphan disease in US could make YK012 one of the first approved TCE in the autoimmune space with many other autoimmune and oncology indications to follow. Excyte would file for US investigational new drug (IND) application imminently.The study aims to evaluate the safety, tolerability, and preliminary efficacy of YK012 in PMN patients. Led by Professor Minghui Zhao and Prof Zhao Cui from Peking University First Hospital, the trial is planned to be conducted across multiple centers in China. The clinical trial for this indication in the United States will be collaboratively executed by Excyte and its international partners.“YK012 is a T-cell engaging bispecific antibody targeting both CD19 and CD3, activating T-cell immunity via CD3 while targeting CD19—the most widely expressed tissue-specific marker during B-cell development and thereby enabling B-cell reset. Our data illustrated YK012 mediated significant B cell depletion and have illustrated in current clinical studies extended half-life and limited cytokine release in patients,” said Mr. Andrew Meng, chairman and COO at Excyte. “We look forward to collaborating with regulatory authorities to make YK012 available to this patient population with a high unmet medical need."In December 2024, YK012 obtained Clinical Trial Approval Notice (No. CXSL2400727) from China's National Medical Products Administration (NMPA) and was registered on ClinicalTrials.gov (NCT06982729). With the first patient dosed in pMN, Excyte now has a global presence in autoimmune diseases in additional to oncology indications such as NHL and ALL. Earlier this year, Excyte also secured clinical trial approval for systemic lupus erythematosus (SLE), with Professor Xiaofeng Zeng from Peking Union Medical College Hospital serving as Principal Investigator.About Excyte Biopharma Ltd.Excyte Ltd. was co-founded by Dr Qing’an Yuan and Mr Andrew Meng , biotech industry veterans with decades of antibody engineering experiences. The company has also established a U.S.-based wholly-owned subsidiary, Excyte LLC, forming a dual-engine drug R&D hub spanning China and the U.S. Excyte is dedicated to developing innovative bispecific antibody drugs for hematologic cancers, multiple myeloma, solid tumors, autoimmune diseases, and other conditions. Excyte’s FIST platform and next generation assets possess features such as long-acting, low-toxicity, and high-yield technological innovations. For more information, please visit https://www.iExcyte.com/Business Development ContactYing Liu, liuying@iExcyte.comReferences:1.William G Couser, Primary Membranous Nephropathy, Clin J Am Soc Nephrol. 2017 May 26;12(6):983–997.2.Elham Ahmadian, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Mohammadreza Ardalan, Novel treatment options in rituximab-resistant membranous nephropathy patients, International Immunopharmacology, Volume 107, 2022, 108635, ISSN 1567-5769. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Financial Performance Highlights for Q3FY2025:Group’s total revenue for the quarter jumps to RM75.1 million, with e-mobility and energy storage segments as primary contributors, followed by electronicsPerformance for the quarter supported by prompt execution of outstanding orders from FY2024 and progress on new scopes secured within existing client baseBoth PBT and PAT stand at RM3.2 million for the quarter under reviewGP, PBT, PAT, and PATAMI margins recorded at 11.6%, 4.3%, 4.3% and 1.1% respectivelyBANGI, Malaysia, May 29, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, GENETEC TECHNOLOGY BERHAD (“Genetec” or the “Company”), today announced its financial results for the third quarter ended 31 March 2025 (“Q3FY2025”). The Company reported a jump in their revenue to RM75.1 million, on par with the preceding year-on-year revenue levels, supported by the delivery of outstanding and new orders across its core client base. Gross Profit (“GP”) for the quarter came in at RM8.7 million with both profit before tax (“PBT”) and profit after tax (“PAT”) at RM3.2 million, and profit after tax and minority interests (“PATAMI”) at RM0.8 million. GP, PBT, PAT, and PATAMI margins stood at 11.6%, 4.3%, 4.3% and 1.1% respectively.While the Q3FY2025 revenue marked a return to revenue levels previously seen in FY2024, profit margins and PAT for the quarter fell compared with the previous quarter’s PAT of RM6.3 million. The Company noted that this was due to several deliveries in the quarter involving new scopes which involved one-off, non-recurring expenses. Genetec expects margin to normalise in upcoming quarters.Managing Director and Co-founder of Genetec, Chin Kem Weng commented, “Our top-line performance reflects a pickup in project execution and a healthy pipeline on the back of our ongoing client engagement. The margin dip this quarter is temporary, contributed by one-off expenses tied to the new project scopes and are not recurring. As such, we are confident that we will see a recovery in the margins in the coming quarters as project maturity and margin discipline for the new scopes improve. Genetec’s focus remains on deepening our partnerships with clients in key sectors like electric vehicle (“EV”), automotives, and energy storage, while we continue to seek meaningful diversification.”Amid the ongoing shifts in global trade dynamics and supply chain strategies, Genetec sees structural tailwinds supporting its growth trajectory. As manufacturers reassess production footprints and strengthen operational resilience, there is an upward demand for flexible, cost-competitive and reliable high-quality automation solutions. Genetec’s Malaysia-based production model, combined with a proven international track record, deep technical expertise, and agile manufacturing capabilities, positions the Company well to support clients adapting to these changes.The Company remains focused on deepening its engagement with existing customers while exploring opportunities to broaden its client base. In addition to pursuing new scopes within existing clients’ operations, Genetec has actively participated in several international exhibitions and industry events in recent months, which have generated encouraging business leads. These engagements mark early steps toward potential entry into new industries and segments, in line with the Company’s longer-term strategy to diversify and grow.Genetec is also actively managing its current production load while progressing its EPIC plant expansion, scheduled for completion in early 2026. The new facility will significantly increase floor space and technical capabilities, supporting Genetec’s ability to deliver on multiple high-value projects simultaneously.“We remain focused on timely order execution, quality and cost control, and supporting our clients in a rapidly evolving industrial and technological environment. With steady project momentum, a growing base of client engagements, and strategic expansion into new sectors, we are cautiously optimistic about the road ahead. We believe Genetec is well-positioned to build on this foundation for long-term growth,” Chin concluded.With ongoing execution across key client projects and growing interest from new industries, Genetec continues to position itself as a trusted global partner in automation.About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/. Copyright 2025 ACN Newswire via SeaPRwire.com.

WILMINGTON, DE, May 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first quantum-resistant blockchain and cybersecurity mesh architecture, has raised $3 million in a strategic funding round led by Mason Labs, that includes Frekaz Group, Level One Robotics and Tradecraft Capital following a six-month technical due diligence process.The round, which includes proceeds from Naoris’s public sale and related allocations, was oversubscribed, prompting the team to open a new institutional raise — now live as of today, Thursday, 29 May.David Carvalho, CEO and Founder of Naoris Protocol, says: “The strong interest we’ve seen from institutions reflects how urgently the industry is beginning to take the threat of quantum computing seriously. This investment supports our mission to future-proof the blockchain ecosystem before these risks become reality.”Mason Labs, a leading venture capital firm focused on infrastructure-grade technologies, conducted a detailed review of Naoris Protocol’s post-quantum trust structure prior to securing the entire VIP allocation.Rain Huan, Founder of Mason Labs, says: “In recent years, cybersecurity issues related to digital assets have become increasingly severe and a serious challenge also faced by Mason Labs as an institution focusing on on-chain asset trading and investment. Naoris Protocol’s groundbreaking infrastructure layer has the potential to effectively mitigate such security risks. If successful, this would represent a substantial advancement for the Web3 ecosystem.”This latest round follows a $31 million fundraise in 2022 backed by Tim Draper, the Holdun Family Office, Expert Doja, Uniera and other institutional investors.Naoris Protocol is led by a team of cybersecurity, defense, and blockchain leaders, including:David Holtzman, former CTO of IBM and architect of the DNS protocolAhmed Réda Chami, Ambassador for Morocco to the EU and former CEO of Microsoft North AfricaMick Mulvaney, former White House Chief of StaffInge Kampenes, former Major General (ret.) and Chief of Norwegian Armed Forces Cyber DefenceThe protocol offers a plug-and-play cybersecurity mesh designed to protect any blockchain or enterprise system from the sub-zero layer upward, without requiring a hard fork. Its decentralized security layer is powered by post-quantum cryptography and AI, and aligned with standards from NIST, NATO, and ETSI.Naoris Protocol also runs a quantum-resistant Layer 1 blockchain secured by its proprietary Proof-of-Security (dPoSec) consensus mechanism.About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks. Naoris Protocol combines Post-Quantum Cryptography, dPoSec Consensus, and Decentralized Swarm AI to create a self-healing security mesh that eliminates single points of failure. Since launching in January 2025, it has processed over 64 million transactions and mitigated 341 million threats. Powered by the $NAORIS token, it is the fastest-growing trust and security layer for a quantum-resilient internet.To learn more about Naoris Protocol, visit https://www.naorisprotocol.com/ Press contact:Anna Fedorovaanna@babslabs.io Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年5月29日 - (亞太商訊 via SeaPRwire.com) - 5 月 22 日，Synology 群暉科技於 COMPUTEX 2025 展示最新產品與服務，包括企業儲存、資料保護、影像監控、企業生產力與個人私有雲的完整解決方案。圖1：Synology 2025 Computex 展示區「Synology 的目標始終是建立一個值得客戶信賴的資料管理生態系。」 Synology 董事長暨執行長翁英暉表示， 「我們設計的解決方案不僅提供高度易用性，更具備領先業界的安全性、可靠性和資料私隱性，讓企業與個人都能安心掌握資料主權。」圖2：Synology 全新旗艦企業級儲存裝置 PAS 7700雙主動式 NVMe 全快閃儲存：PAS7700PAS7700 是 Synology 全新旗艦企業級儲存裝置，專為關鍵任務工作負載而打造，具備雙控制器主動式架構，確保服務持續不中斷。同時以安全為核心，內建 3-2-1-1 資料保護能力，並從各層面保障資料完整性。PAS7700 提供卓越效能與極致成本效益，採用端對端 NVMe 架構，提供高達 200 萬 IOPS 與低於毫秒的延遲，效能比現有 Synology 機種高出 3 倍。圖3：Synology 全新ActiveProtect 備份專用一體機 DP7200全新 ActiveProtect 備份專用一體機：DP7200繼推出 ActiveProtect DP7400 之後，Synology 宣布全新 DP7200 上市，進一步擴展資料保護產品線。DP7200 可作為分支據點的獨立備份伺服器，亦能於總部作為 CMS 控制中心，依企業需求靈活部署。DP7200 可集中管理組織內的多元工作負載，並內建不可變快照與網路隔離功能，有效防範資安威脅，確保企業隨時擁有可用的乾淨還原版本。圖4：Synology 全新雲端 VMS 系統 C2 SurveillanceSynology 全新雲端 VMS 系統：C2 Surveillance在既有的本地端影像監控生態系統之上，Synology 推出基於雲端的影像管理系統 C2 Surveillance，無需 NVR 伺服器即可部署，適用更多元的監控場景。C2 Surveillance 專為快速架設和輕鬆擴展而打造，透過雲端集中管理、整合 Windows AD 以及細緻權限分配，相當適合大規模、多站點部署。同時支援邊緣錄影與故障備援模式，確保不錯過任何一個關鍵時刻。圖5：Synology 生產力應用套件展示區生產力應用升級：ChatPlus 與 Synology Meet為滿足企業高效且安全的內部溝通，Synology Office Suite 將帶來新成員：Synology ChatPlus 與 Synology Meet。ChatPlus 提供安全的團隊溝通環境，支援細緻權限設定與頻道管理；Synology Meet 則是為企業打造的專業級視像會議解決方案。兩款套件皆運行於 Synology 的私有雲架構，企業得以完整掌控資料並確保高度隱私性。圖6：Synology Digital Life 系列新品- BeeStation Plus專為個人設計的私有雲：BeeStation PlusBeeStation Plus 是專為個人使用者設計的私有雲解決方案，可自動備份 iCloud 相簿，並整合 Plex Media Server，提供無縫串流體驗。透過 BeeProtect，則支援快照還原與異地備份功能，守護珍貴的資料與回憶。同時，搭配 Synology CC400W 攝影機，BeeStation Plus 亦提供智慧家庭監控功能。透過全新流動應用程式，可即時偵測人員出入、寵物活動、環境聲響與異常破壞行為，並即時發送通知，讓用戶隨時掌握家中狀況。圖7：Synology 香港代理商、當地合作夥伴與 Synology 高階業務管理團隊合影COMPUTEX 現場同步展出 Synology 最新 25 系列產品、雲端創新應用以及 AI 技術成果。本次展覽也獲得國際合作夥伴的熱烈支持，均有來自香港當地代理商與重要合作夥伴皆親臨現場共襄盛舉，展現對 Synology 長期合作關係的重視；此外，香港地區亦邀請多家知名 商業媒體與科技媒體出席，讓這場盛會增添更多國際關注與專業洞見。欲了解更多Synology群暉科技產品和解決方案詳情或有任何需求，歡迎至Synology群暉科技官網或聯繫 hk.event@synology.com圖片下載：https://bit.ly/3SdGUHp關於 Synology 群暉科技成立於 2000 年，Synology 專注於資料管理領域，提供資料儲存、備份、檔案協作、影像監控管理以及網路架構解決方案，目前在全球已累積超過 1000 萬名用戶，並在網路儲存設備 （NAS）專業使用者及企業市場取得領先地位。隨著資料成為各產業轉型核心，未來 Synology 將持續協助全球企業妥善管理、保護每一份資料，簡化 IT 管理流程。媒體聯繫窗口：Sandra Soh (Synology Regional Marketing）Email : sandrasoh@synology.com聯繫電話：+886 0905027104Andico Tsui (Senior Account Manager of SPRG)Email: andico.tsui@sprg.com.hk聯繫電話：+852 2114 4346 / 6902 3831 Copyright 2025 亞太商訊 via SeaPRwire.com.

- ASGH brought together more than 2,900 participants from 42 countries and regions- Medical Fair attracted some 13,000 buyers from 57 countries and regions- The two flagship events together resulted in over 390 deal-making sessions and more than 660 business matching meetings- Collaboration agreements were signed during the events, covering areas including patient care, diagnostic solutions, innovative medical devices, and medical imagingHONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – The fifth Asia Summit on Global Health (ASGH) and the 16th Hong Kong International Medical and Healthcare Fair (Medical Fair), both organised by the Hong Kong Trade Development Council (HKTDC), have drawn to a successful close. As flagship events of International Healthcare Week (IHW), both ASGH and the Medical Fair brought global healthcare stakeholders together, including government officials and organisations, research pioneers, investors, and business leaders. ASGH attracted over 2,900 participants from 42 countries and regions, while the Medical Fair received some 13,000 buyers from 57 countries and regions. Over 390 one-on-one deal-making sessions and more than 660 business matching meetings were arranged, facilitating over 1,000 high-quality collaborations and connections. The IHW continues to foster global exchange and cooperation, putting a spotlight on Hong Kong’s vast potential in healthcare investment and trade, and reinforcing its position as a regional leading medical hub.Dr Peter K N Lam, Chairman of the HKTDC, said: "The Asia Summit on Global Health and the Hong Kong International Medical and Healthcare Fair concluded with outstanding results driving new collaborations and investments, and injecting new momentum into the healthcare industry. The events brought together leaders across government, business, academia, and investment to tackle today’s healthcare challenges, highlighting Hong Kong’s unique advantages as an international innovation and technology hub under its ‘eight centres’ positioning, actively advancing medical technology, connecting global innovation resources, and paving the way for a healthier and more inclusive future."Over 80 industry experts shared insights on healthcare developmentThe two-day ASGH, jointly organised by the HKSAR Government and the HKTDC under the theme ‘Fostering Global Collaboration for a Shared Future’, focused on a wide spectrum of topics including public health, medical technology breakthroughs, healthy ageing and global business and investment collaboration. The event featured more than 80 speakers comprising government officials and organisations, research pioneers, investors, and business leaders from around the world, all contributing valuable insights to advance global well-being.Prof Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech during the Plenary Session I: Shaping a More Equitable and Sustainable Health System. Other distinguished speakers, including Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; Martin Taylor, Representative to China, World Health Organization; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; and Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association, shared their insights on tackling global healthcare challenges, offering inspiration for the international healthcare community.In Plenary Session II: Fostering Global Collaboration for a Shared Future, speakers engaged in a lively discussion on trends in global healthcare collaboration. Among them was Ambassador George Hara, Group Chairman and CEO of DEFTA Partners and former Special Advisor to the Cabinet Office of the Prime Minister of Japan, who remarked that more advanced technology and new government regulations are needed to reach a compromise between companies' profits and patients' needs.During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, shared his latest research findings and advanced developments in Alzheimer's disease.The summit co-organised sessions under the overarching theme, Shaping the Future of Healthcare, with the Hong Kong University of Science and Technology for the first time. The discussion focused on the potential of AI in healthcare and how innovation could drive breakthroughs in the field. Dr Alex Ng, President of Tencent Healthcare, commented: “One uniqueness of tech companies is that they can be easily distracted by the latest thing. But you do need companies with patience and perseverance to stay in healthcare and make it work.” Prof Graham Cooke, Vice-Dean (Research) Medicine of Imperial College London, also noted that embedding patient needs into healthcare systems is critical, as many innovations fail in translation due to a lack of this focus, with universities playing a key role as innovation drivers.In Beyond ‘Healthy China 2030’: Driving Health Innovation, speakers explored opportunities in the mainland healthcare market. Marc Horn, Executive Vice President of Merck and President of Merck China, highlighted the two-phase approach of "China for China" followed by "China for the globe”, emphasising healthcare collaboration to develop advanced treatments for global benefit. Dr Zhang Lianshan, Executive Vice President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., stated: "We would like to see our health innovation have realisation of its value, not only in China, but also outside of China. That is why we are talking about Globalisation, where we can achieve maximum value."With growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing, Prof James L. Kirkland, Director of Cedars-Sinai’s Centre for Advanced Gerotherapeutics, and fellow experts explored both the challenges and opportunities posed by ageing populations. Prof Jean Woo highlighted that rapid population ageing is reshaping the global healthcare and socioeconomic landscape. As a city with one of the world’s longest life expectancies, Hong Kong must take early action to strengthen elderly care policies and better allocate health resources. Prof James L. Kirkland also noted that geriatricians ultimately aim to help patients with multiple illnesses reduce medication use while treating their conditions more effectively, enhancing their overall quality of life.Over 390 deal-making sessions and cooperation agreements open new global opportunitiesA key feature of the summit was the ASGH Deal-Making session, which facilitated one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Investment projects spanned pharmaceuticals, medical devices and diagnostics, smart healthcare, and community health and wellness and more than 390 one-on-one meetings were successfully arranged for angel investors, venture capitalists, corporate venture arms, private equity firms and family offices.The summit facilitated the signing of cooperation agreements, such as those between Gleneagles Hospital Hong Kong and Emerging Viral Diagnostics, and a tripartite collaboration with PanopticAI and SmartCare, HKSH Medical Group and United Imaging Healthcare, China Resources Guangdong Pharmaceuticals and Hong Kong Medtech Association, Hugobiotech and Bridgeway Healthcare Technology, Canossa Hospital and KA Imaging, and others. These agreements covered diverse healthcare areas, including patient care, diagnostic solutions, innovative medical devices, medical imaging and more. Under the tripartite collaboration agreement between Gleneagles Hospital Hong Kong, PanopticAI, and SmartCare, the integration of PanopticAI’s camera-based vital signs monitoring technology and SmartCare’s patient-centered consultation platform will be implemented into Gleneagles clinic in the future.In addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative technology companies related to the healthcare industry from 13 countries and regions, including the mainland (Shanghai and Xiamen), Australia, and Thailand, presenting projects and solutions across key areas such as medical innovation, smart healthcare, AI, big data, telemedicine, and cybersecurity. Zhong Wei, Co-founder of Mitrassist Lifesciences, joined the Shanghai Pavilion and said that ASGH helped them bring non-invasive medical monitoring technologies to Southeast Asia, Africa, and other Belt and Road Initiative countries.Medical Fair Drives Industry Innovation and Fosters Business CollaborationThe Medical Fair, organised by the HKTDC and co-organised by the Hong Kong MedTech Association, was held alongside ASGH. The Association—formerly known as the Hong Kong Medical and Healthcare Device Industries Association—held a renaming ceremony during the fair, showcasing the deep integration of medical technology and the industry.The fair brought together some 300 exhibitors from 13 countries and regions, featuring first-time pavilions from the United Kingdom, Thailand and Israel, along with debut exhibitors from Singapore, Germany, Italy and Luxembourg. In addition, seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks pavilion, and more than 20 medical enterprises brought by the Hong Kong MedTech Association participated. The Hong Kong Council of Social Service also participated in the fair for the first time. Under the theme Innovations Boosting Smart Health Experience, the exhibition spotlighted three major areas: MedTech, GeronTech and green solutions, with many exhibits featuring applications of AI.Many exhibitors and buyers successfully expanded their networks and forged new partnerships at the exhibition. Among them was Hong Kong exhibitor Eieling Technology, a company founded to commercialise research outcomes from the Hong Kong Polytechnic University. The firm showcased its non-invasive liver examination technology, which utilises transient elastography technology. Co-founder and CEO Xiaojia Jia noted that only about four companies worldwide possess this technology, making it a major draw for buyers. "During the exhibition, we received intention orders worth several million Hong Kong dollars from mainland China, Hong Kong, Indonesia, and Thailand, involving around ten devices. This is our third year participating, and we've observed a significant rise in buyers' professionalism during our discussions. We look forward to exhibiting again next year."Karel Lee, CEO of Neoneco from Korea, sourced innovative medical products at the fair with a minimum budget of USD100,000 and he has already identified RhinoCare, an exhibitor from the Israeli pavilion, for its nasal decongestion device, and is also interested in a medical examination device from a Hong Kong exhibitor. Lee stated, "The exhibition allows us to meet with exhibitors face-to-face, build trust, and accelerate the decision-making process. The HKTDC’s Click2Match platform also facilitated efficient business matching. I have already connected with ten exhibitors, and another twenty reached out to me after learning about my sourcing needs. This is one of Asia's premium medical sourcing events, and we will definitely return next year."Beyond business deals, insightful forums were arranged during the Medical Fair to give inspiration to industry buyers. These included The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area, The MedTech Nexus of the Greater Bay Area, co-organised with the Hong Kong MedTech Association, and Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices, co-organised with the HKCSS. These forums attracted a strong attendance and offered valuable insights into healthcare. Selected sessions are available for replay on the Fair’s website for extended engagement.This year’s Fair continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing (hktdc.com Sourcing). Click2Match will remain available until 4 June.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enPhoto download: https://bit.ly/4kbr9NcThe fifth Asia Summit on Global Health was attended by over 2,900 participants from 42 countries and regionsProf Lo Chung-mau, Secretary for Health of the HKSAR Government, delivered a keynote speech on the first day during the Plenary Session I: Shaping a More Equitable and Sustainable Health SystemProf John Hardy, Chair of Molecular Biology of Neurological Disease at UCL Queen Square Institute of Neurology. As an internationally renowned neurogeneticist, Prof John Hardy has been awarded the Brain Prize for "groundbreaking research on the basis of Alzheimer's disease" and is known as the “father of Alzheimer’s disease genetic studies”. He shared his latest research findings and advanced developments during the Dialogue with Global Pioneer in Health sessionWith growing global attention on healthy ageing, the summit introduced a dedicated Silver Health Chapter for the first time. A highlight was the thematic session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, where Prof Jean Woo, Director of Chinese University of Hong Kong Jockey Club Institute of Ageing (far left), and fellow experts explore the challenges and opportunities posed by ageing populationsIn addition to its discussion sessions, the summit also featured the ASGH Business Hub, showcasing more than 170 innovative solutions from the healthcare industry across 13 countries and regionsASGH Deal-making facilitated over 390 one-on-one meetings(Front row from the left) Dr Kyle Wong, Chief Executive Officer and Co-founder of PanopticAI Limited, Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, and Dr Justin Cheng, Chief Executive Officer and Co-founder of SmartCare Technology Co Limited signed a tripartite cooperation agreement witnessed by (back row from the left) Prof Nancy Ip, President of The Hong Kong University of Science and Technology, Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare and Patrick Lau, Deputy Executive Director of Hong Kong Trade Development CouncilThe 16th Hong Kong International Medical and Healthcare Fair attracted some 13,000 buyers from 57 countries and regions who visited the fair for sourcing and procurementThe Hong Kong MedTech Association had a delegation of over 20 companies participating in the fair, attracting strong interest from buyers who engaged with exhibitors to explore business opportunitiesThe United Kingdom pavilion, participating in the Medical Fair for the first time, promoted innovative medical devices, solutions and services from multiple companies at the fairAn expert from the Greater Bay Area Center for Medical Device Evaluation and Inspection of the National Medical Products Administration; Eva Wong, Senior Electronics Engineer, Medical Device Division of Department of Health (pictured); along with SGS-CSTC Standards Technical Services Co., Ltd.’s expert, shared insights at The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area forumCo-organised by the Hong Kong Council of Social Service, the Fostering Silver Economy, Leading Quality Elderly & Rehabilitation Care Practices forum drew a strong turnout from industry professionalsMedia enquiriesFor enquiries, please contact Yuan Tung Financial Relations Limited:Louise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Asia Summit on Global HealthSharon HaTel: (852) 2584 4575Email: sharon.mt.ha@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgHong Kong International Medical and Healthcare FairKelly ShekTel: (852) 2584 4537Email: kelly.yt.shek@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, May 28, 2025 - (ACN Newswire via SeaPRwire.com) – Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, announced the successful launch of the 30th Anniversary Celebration and Symposium “Hexallence Beyond 30: Pioneering Tomorrow’s Dentistry” by its Thai subsidiary Hexa Ceram Dental Laboratory (“Hexa Ceram”) in Bangkok, Thailand on 24th May. As a crucial segment of Modern Dental Group's strategic framework in the Asia-Pacific region, Hexa Ceram's 30th anniversary celebration is not only a milestone for the industry but also marks a new starting point for the collaborative development of both parties.In the 30 years since its establishment in 1995, Hexa Ceram has been committed to promoting innovation in dental technology. By 2023, its local market share reached 29%, making it the top dental laboratory in Thailand. It has become a benchmark company in the dental field in Thailand and Southeast Asia. Themed "Pioneering Tomorrow’s Dentistry", this year's celebration aims to review the technological advancements and industry contributions of the brand over the past 30 years, and to open up a forward-looking vision in dentistry for practitioners through insightful discussions with top-tier scholars globally. The symposium specially invited 300 dentists, 100 VIP customers in the industry, dean from 10 top universities and presidents of dental associations to jointly build a blueprint for the future development of dentistry. At this new milestone, Hexa Ceram is dedicated to delivering high-quality and innovative dental solutions and services continuously. It is committed to expanding the presence in the ASEAN Economic Community, fostering growth and excellence in dental care.The global dental industry is currently undergoing an accelerated transformation from traditional models to precision-driven and intelligent approaches. With Hexa Ceram officially incorporated into the global system of Modern Dental Group, the two parties will continue to strengthen their leadership in the Thai market through technological innovation, resource synergy and integration, and effectively promote the Group's competitiveness in the global dental industry value chain. Looking ahead, the Group will continue to maintain its focus on digital innovation as a catalyst and give full play to the strategic role of Hexa Ceram to build a dental ecosystem network in Southeast Asia. Through international technology integration, service model advancements and global resource collaboration, we strive to elevate oral diagnosis and treatment technology in Southeast Asia and globally, delivering transformative dental solutions.About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, and Apex Digital Dental in Malaysia. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com.